Clinical trials: Patients With Diabetes.
Type2diabetes
A Post-Marketing Safety Study of Dorzagliatin in Patients With Type 2 Diabetes
The primary objective of this study is to evaluate the long-term safety of Dorzagliatin in a larger population of type 2 diabetes mellitus patients by collecting the post-marketing clinical safety data of Dorzagliatin.
- Trial name
- BLOOM (NCT06263348)
- Testing
- Dorzagliatin tablets
- Where
- China
- Volunteers
- 2,024 people
- Sponsor
- Hua Medicine Limited
Type 2 Diabetes
Dose Response Study in Japanese Patients
This is a 12-week study to determine the effect on glucose and lipids, safety, and tolerability of four doses of tesaglitazar (0.25, 0.5, 0.75 and 1 mg) compared with placebo in patients with type 2 diabetes.
- Trial name
- NCT00261417
- Testing
- Tesaglitazar
- Where
- 20 sites in Japan
- Volunteers
- 250 people
- Sponsor
- AstraZeneca
Type 1 Diabetes
A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 1 Diabetes Mellitus
The purpose of this study is to compare long-acting basal insulin analog LY2963016 to Lantus® in combination with mealtime insulin lispro in adult Chinese participants with Type 1 Diabetes Mellitus (T1DM).
- Trial name
- NCT03338023
- Testing
- LY2963016, Lantus®, Insulin Lispro
- Where
- 20 sites in China
- Volunteers
- 272 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
A Study to Assess the Acute Effects of Vildagliptin on Gastric Emptying in Patients With Type 2 Diabetes.
Please note this study is not being conducted in the United States. The purpose of this study is to assess the acute effects of vildagliptin, an unapproved drug, in reducing post-meal glucose levels by delaying gastric emptying.
- Trial name
- NCT00380380
- Testing
- Vildagliptin
- Where
- Germany
- Volunteers
- 18 people
- Sponsor
- Novartis
Diabetes Mellitus Type 2
GLYCOSA Study:Effect of PAP Treatment on Glycemic Control in Patients With Type 2 Diabetes
Obstructive Sleep Apnea (OSA) and type 2 diabetes mellitus are two prevalent medical conditions with significant associated cardiovascular and cerebrovascular morbidity and mortality.
- Trial name
- NCT00509223
- Testing
- Positive Airway Pressure therapy, Lifestyle counseling
- Where
- 15 sites in United States, Australia and 1 more
- Volunteers
- 416 people
- Sponsor
- ResMed
Diabetes Mellitus, Type 2
Study of Insulin Lispro in Participants With Inadequately Controlled Type 2 Diabetes
Evidence regarding optimal methods of insulin dose adjustment is lacking in the literature. The purpose of this study is to evaluate the efficacy and safety of two approaches to escalate prandial insulin therapy in participants…
- Trial name
- AUTONOMY (NCT01215955)
- Testing
- Insulin lispro, Glargine
- Where
- 76 sites in United States, Argentina and 13 more
- Volunteers
- 1,117 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1
A Study of LY900014 in Japanese Participants With Type 1 Diabetes Mellitus
This study will compare LY900014, a drug that lowers blood sugar, with insulin lispro (Humalog). Both drugs will be given by injection under the skin of the abdomen.
- Trial name
- NCT03407118
- Testing
- LY900014, Insulin Lispro
- Where
- Japan
- Volunteers
- 31 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus
Evaluation of an Ascensia Diabetes Care Blood Glucose Meter and App System
The purpose of this study is to assess the utility of the Contour Diabetes App 2.0 when used with the Contour Next One meter (the Onyx system).
- Trial name
- NCT03165110
- Testing
- Onyx BG Meter / App System
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Ascensia Diabetes Care
Diabetes Mellitus, Type 2
Insulin Glulisine in Diabetes Mellitus, Type 2
Primary objective: The primary study objective is to demonstrate superior efficacy of an intensified insulin regimen with insulin glulisine and insulin glargine to a two-injection conventional insulin regimen in terms of change…
- Trial name
- GINGER (NCT00174668)
- Testing
- Insulin Glulisine, Insulin Therapy, Insulin Glargine
- Where
- 15 sites in Australia, Belgium and 13 more
- Volunteers
- 311 people
- Sponsor
- Sanofi
Cardiovascular Disease, Diabetes Mellitus Type 2
A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities
This randomized, double-blind, placebo-controlled, parallel group, multicenter study will evaluate the potential of aleglitazar to reduce cardiovascular risk in patients with stable cardiovascular disease and glucose…
- Trial name
- NCT01715818
- Testing
- aleglitazar
- Where
- 392 sites in United States, Argentina and 25 more
- Volunteers
- 1,999 people
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus Type 2
Comparison of Two Basal Insulins for Patients With Type 2 Diabetes (IOOY)
The purpose of this study is to examine the effectiveness and safety of insulin lispro protamine suspension (ILPS) as compared to insulin detemir as basal insulin therapy in adults with type 2 diabetes.
- Trial name
- IOOY (NCT00494013)
- Testing
- Insulin Lispro Protamine Suspension, Detemir
- Where
- 56 sites in United States, Argentina and 7 more
- Volunteers
- 442 people
- Sponsor
- Eli Lilly and Company
Type2 Diabetes
Efficacy and Safety of AJU-A51 in Type 2 Diabetes Mellitus Patients
A multicenter, randomized, double-blind, parallel group, placebo-controlled, phase 3 study to evaluate the efficacy and safety of the combination of A51R3 and AJU-A51 compared with the combination of A51R3 and A51R2 in patients…
- Trial name
- NCT06329674
- Testing
- AJU-A51, A51R2, A51R3
- Where
- South Korea
- Volunteers
- 235 people
- Sponsor
- AJU Pharm Co., Ltd.
MASH, MASLD
Global Research Initiative for Patients Screening on MASH
GRIPonMASH will assist (primary) health care providers clinicians to implement the latest patient care pathway, as described by the European Association for the Study of the Liver (EASL), to identify patients at risk of severe…
- Conditions
- MASH, MASLD, MASH With Fibrosis, Fibrosis, Liver
- Trial name
- GRIPonMASH (NCT05651724)
- Where
- 13 sites in Belgium, Czechia and 8 more
- Volunteers
- 10,000 people
- Sponsor
- Julius Clinical
Type 1 Diabetes Mellitus
An Open Label, Multi-Center, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Insulin VIAject™ and Regular Human Insulin in Patients With Type 1 Diabetes Mellitus
The purpose of this study is to demonstrate equivalent blood glucose control in patients with type 1 diabetes mellitus with insulin VIAject™ and regular human insulin as prandial insulin and to demonstrate an equivalent safety…
- Trial name
- NCT00542724
- Testing
- VIAject™, Regular Human Insulin
- Volunteers
- 462 people
- Sponsor
- Biodel
Diabetes Mellitus, Type 2
Pre-Mix Insulin Lispro Treatment for Type 2 Diabetes Patients Who Consume a Light Breakfast
This study is designed to look at how best to start and then gradually intensify (as needed) the insulin lispro premix regimen in type 2 diabetes patients who consume a light breakfast.
- Trial name
- NCT00664534
- Testing
- Insulin Glargine, Insulin Lispro Premix (mid-mixture and low-mixture)
- Where
- 27 sites in Canada, Egypt and 6 more
- Volunteers
- 344 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Drug Naive Patients With Type 2 Diabetes
Many people with type 2 diabetes cannot maintain target blood glucose levels when taking a single oral drug. The purpose of this study is to assess the safety and effectiveness of the combination of vildagliptin, an unapproved…
- Trial name
- NCT00101803
- Testing
- vildagliptin
- Where
- United States
- Volunteers
- 527 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes, Type 2
A Phase 3 Study of OPC-262 in Patients With Type 2 Diabetes
The purpose of this study is to investigate the safety of OPC-262 administered orally in combination with another oral antihyperglycemic agent
- Trial name
- NCT01193179
- Testing
- OPC-262
- Where
- 4 sites in Japan
- Volunteers
- 450 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Type 2 Diabetes Mellitus With Diabetic Nephropathy
Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria
NADPH oxidase enzymes (NOX) have been implicated in the development of several diabetic complications including diabetic nephropathy. GKT137831 is the first in class NOX1/4 inhibitor.
- Trial name
- NCT02010242
- Testing
- GKT137831
- Where
- 48 sites in United States, Australia and 4 more
- Volunteers
- 136 people
- Sponsor
- Calliditas Therapeutics AB
Hypertension
An Observational Study to Describe the Effectiveness of Angiotensin Converting Enzyme Inhibitor and Calcium Channel Blocker Combination in the Management of Hypertensive Patients With Elevated Heart Rate and Type 2 Diabetes
To describe the effectiveness of angiotensin-converting enzyme inhibitor and non-dihydropyridine calcium channel blocker single pill combination on systolic blood pressure (SBP) lowering in hypertensive patients with elevated…
- Trial name
- HARVEST-TR (NCT02298556)
- Where
- 23 sites in Turkey (Türkiye)
- Volunteers
- 270 people
- Sponsor
- Abbott
Diabetes Mellitus, Type 2
Linagliptin Among Filipino Patients With Type 2 Diabetes Mellitus
This is a prospective, non-interventional, open label, multi center, post marketing surveillance study designed to assess the safety, tolerability and efficacy of Linagliptin among Filipino patients with type 2 Diabetes Mellitus…
- Trial name
- NCT01826370
- Testing
- Linagliptin
- Where
- 51 sites in Philippines
- Volunteers
- 678 people
- Sponsor
- Boehringer Ingelheim